iX Biopharma Ltd

42C

Company Profile

  • Business description

    iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are the Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in the United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.

  • Contact

    1 Kim Seng Promenade
    No. 14-01
    Great World City East Lobby
    Singapore237994
    SGP

    T: +65 62352270

    https://www.ixbiopharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    30 June 2026

    Employees

    51

Stocks News & Analysis

stocks

Progress in UK expansion for undervalued ASX share

Guidance reaffirmed and UK implementation on track.
stocks

The sectors set to soar on government spending

Governments worldwide love to spend more money, and there are no signs that it will change any time soon.
stocks

Chart of the Week: How private companies are reshaping public markets

Our latest take from the US Manager Research team.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,071.2019.30-0.21%
CAC 408,074.236.700.08%
DAX 4024,049.74100.630.42%
Dow JONES (US)47,397.02311.780.66%
FTSE 1009,777.0862.120.64%
HKSE25,935.4116.99-0.07%
NASDAQ23,614.15265.511.14%
Nikkei 22550,212.271,284.93-2.50%
NZX 50 Index13,620.9815.020.11%
S&P 5006,824.5152.960.78%
S&P/ASX 2008,802.007.80-0.09%
SSE Composite Index3,969.259.060.23%

Market Movers